Short answer
Pacira BioSciences, Inc. (PCRX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 7.01 (Regulation FD Disclosure). Viatris’ tender offer values Pacira at $36.50 per share in cash, subject to withholding taxes and transaction conditions.
Pacira BioSciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Viatris’ tender offer values Pacira at $36.50 per share in cash, subject to withholding taxes and transaction conditions
- Pacira expected to become Viatris’ wholly owned subsidiary following the merger
- No September 30, 2026 quarterly earnings release or conference call during the proposed transaction
- Pacira withdrew previously issued 2026 financial guidance, removing near-term operating visibility
- Investor focus shifts to offer completion, regulatory approvals and minimum tender condition risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Pacira BioSciences, Inc. 8-K filings
Get the next PCRX 8-K as it lands
Follow PCRX for push alerts, or ask the research agent what this filing means.